

The Prostate Cancer Foundation (PCF) and Pfizer Inc.

**Independent Medical Education
Improving Advanced Prostate Cancer
Management in Latin America**

Visiting Professorship Program

Request for Proposals (RFP)

I. Background

About the Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has been responsible for raising more than \$1 billion in support of cutting-edge research by more than 2,250 research projects at 245 leading cancer centers, with a global footprint spanning 28 countries. Since PCF's inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease. Learn more at pcf.org.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. Pfizer's GMG competitive grant program involves a publicly posted **RFP** that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

About the Visiting Professorship (VP) Program

This RFP is to provide financial support to organizations to host and coordinate a two-day medical education program at the organization, to be led by two international Visiting Professors with expertise matched to the organization's unmet educational needs surrounding the management of advanced prostate cancer. Healthcare practitioners, researchers and patients will benefit from the knowledge and on-site presence of distinguished medical experts who might otherwise be inaccessible.

Our support to this first-time competitive VP Program for Latin America, reflects our commitment to improve outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and

education for healthcare professionals in Latin America.

The goals of this program are to provide meaningful practice-based educational experiences for oncology-care teams in Latin America, building capacity in Latin American cancer medicine by identifying gaps in patient care and assisting with solutions, and building global collaborations between Latin American and Western oncology care professionals.

II. Eligibility

Geographic Scope:	Argentina, Brazil, Chile, Colombia and Mexico.
Institutions Eligibility Criteria:	<ul style="list-style-type: none">• Applicant (Principal Investigator; PI) must have a medical degree (MD, MBBS, or equivalent), and hold a position as a medical oncologist seeing patients with prostate cancer in the respective market.• Principal Investigator should serve as Chair of the proposed VP two-day medical education program.• Applicants must be from healthcare/medical organizations that provide comprehensive medical care for patients with advanced prostate cancer, located in Argentina, Brazil, Chile, Colombia, or Mexico.• The institution and medical hosting team must be based in the scoped Countries.• Only institutions / organizations / associations are eligible to receive Grants, not individuals or medical practice groups.• Institutions applying for this grant must have proven oncology-care capacity to host this Visiting Professorship.• The project can involve multiple departments within an institution and/or between different institutions / organizations / associations. In this case all institutions must have a relevant role and the requesting organization must have a key role in the project.• The project/program lead must be an employee or independent contractor of the requesting organization.• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants approved to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

III. Requirements

Date RFP Issued:	February 8, 2024
Clinical Area:	Oncology – Genitourinary – Prostate Cancer
Area of Interest for this RFP:	<p>The intent of this Request for Proposal (RFP) is to invite academic oncology health institutions to submit applications to host a two-day medical education program at the organization, to be led by two Visiting Professors with expertise matched to the organization’s unmet educational needs surrounding the management of advanced prostate cancer.</p> <p>Application proposals from Organizations interested in hosting this program must include but not limited to the following information:</p> <ul style="list-style-type: none">• Description of Organization’s mission, vision, impact, and reach. This includes statistics and descriptions of the following:<ul style="list-style-type: none">• Mission and Vision.• Numbers of hospitals and clinics in organization; regional reach and coverage.• Numbers of patients served and patient visits.• Numbers of hospital staff, including all employees, clinical faculty, registered nurses, medical residents and fellows, medical students, and academic faculty and students.• Prevention, screening, diagnosis, and treatment services, certifications and specialties.• Clinical trials.• Educational platforms and programs.• Any innovation or research breakthroughs.• Description of the Organization’s medical gaps, unmet needs, challenges, and questions surrounding the management of patients with advanced prostate cancer, for which a Visiting Professor could provide education. Relevant clinical information for the development of the program may include but is not limited to:<ul style="list-style-type: none">• Training needs of the healthcare team including physicians, nurses and other allied health professionals.• Cancer care disparities that can be impacted with this program.• Treatment algorithm or sequencing challenges.• Agenda for a two-day medical education program that should include but is not limited to:<ul style="list-style-type: none">• Description of desired expertise from two out-of-country physicians (“Visiting Professor”) representing different

	<p>medical disciplines (e.g., urology, medical oncology, radiation oncology, nuclear medicine, radiology, survivorship, etc.)</p> <ul style="list-style-type: none"> • Example agenda for meetings during two-day program including a combination of lectures, patient case reviews, informal discussions, and other meaningful interactions with the local care team that would be facilitated. This Program is expected to be held in English due to the International Visiting Professors but can have simultaneous translation to Spanish or Portuguese if needed (costs can be reflected in the operational budget). • Expected number of health care professionals attending this Program (e.g., own site physicians, invitees from satellite oncology sites or allied healthcare institutions, etc.) • Expected local faculties, speakers, etc. <ul style="list-style-type: none"> • Budget template for all <u>local</u> costs that can include, meeting rooms, AV, local onsite management, local faculty fees, onsite logistics, planning and staffing, simultaneous translation, not to exceed \$30,000 USD. Travel expenses and honoraria for the Visiting Professors will be covered directly and should not be included in the budget. • Expected / desired results and outline of 12-month outcome metrics for Visiting Professorship Program that will report on enduring changes that have occurred in improvements in patient care and physician education/knowledge. A 30-day report on activities and outcomes that occurred during the Visiting Professorship Program will also be required. This report can include but is not limited to details on: <ul style="list-style-type: none"> • Impact on patient management and outcomes • Impact on physician education and knowledge • Sustainability of practice changes • Potential replicability and dissemination • Collaborations with other oncology sites, medical societies, academia, etc. • Publications and/or communications plan
Target Audience:	<p>Medical oncologists should serve as Principal Investigator (PI) and Program Chair, but all other medical disciplines can be included in the Program plan, such as: radio-oncologists, allied prostate cancer healthcare providers, and urology, pathology and nuclear medicine MDs.</p>

Expected Approximate Monetary Range of Grant Applications:	<ul style="list-style-type: none"> Individual Grant amounts will be up to \$30,000 USD to cover for local costs related to this program. Please note: PCF will select two international Visiting Professors based on the approved program and its knowledge gaps. Travel expenses and honoraria for the Visiting Professors will be covered separately and are not part of this Grant budget. Approximately five sites will be supported by this educational program. Applications will be reviewed by an expert review panel (ERP) The amount of the award will depend upon the expert review panel's evaluation of the proposal and costs involved and will be stated clearly in the award agreement.
Key Dates:	<ul style="list-style-type: none"> RFP release date: February 8, 2024 Grant Application due date: April 4, 2024. Please note the deadline is 23:59 Eastern Time (New York, GMT -5). Review of applications by ERP: May 2024 Anticipated Grant Award Notification Date: June 2024 Grants will be distributed following a fully executed agreement. Anticipated Project Start and End Dates: July 1, 2024, to July 31, 2025

How to Apply:	<p>Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.</p> <ul style="list-style-type: none"> Please go to https://www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click "Create your password". <i>[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]</i> In the application: <ul style="list-style-type: none"> For the question "What type of request are you submitting?" select "Support for a Visiting Professorship". For the question "Are you replying to a Request for Proposal as part of the Competitive Grant Program?" select Yes Select the following Competitive Grant Program Name: 2024 ONC LATAM Improving Advanced Prostate Cancer Management in Latin America IME. Select the following Primary Area of Interest: Oncology – Genitourinary - KG; Select Genitourinary – Prostate for the Cancer Type Detail question. Requirements for submission: <ul style="list-style-type: none"> Complete all required sections of the online application and
----------------------	---

	<p>upload your project proposal in the Proposal/Protocol field.</p> <ul style="list-style-type: none"> If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed.</p>
Questions:	<p>If you have questions regarding this RFP, please direct them in writing to Miguel Briceno (Miguelangel.briceno@pfizer.com) at with the subject line: <i>2024 ONC LATAM Improving Advanced Prostate Cancer Management in Latin America IME</i>.</p>
Grant Agreements:	<ul style="list-style-type: none"> If your Grant application is approved, your Institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety. Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application. Except where prohibited by applicable local laws or regulations and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization in its country of domicile. This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
Review and Approval Process:	<ul style="list-style-type: none"> Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions. The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement.

Mechanism by which Applicants will be Notified:	<ul style="list-style-type: none">• All applicants will be notified via email by the dates noted above.• Applicants may be asked for additional clarification during the review period.
--	--